drugset / Trial / NCT00983437

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437

Phase 3 Terminated 49 enrolled Cephalon
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety and tolerability of long-term (12 months) armodafinil treatment in patients with excessive sleepiness associated with mild or moderate closed traumatic brain injury (TBI).

Timeline

Start
2009-08-31
Primary completion
2011-01-31
Completion
2011-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Armodafinil Small molecule 150 mg Oral
Subject Armodafinil Small molecule 250 mg Oral